EP4724056A2 — Epinephrine liquid formulations
Assigned to Fresenius Kabi USA LLC · Expires 2026-04-15 · 0y expired
What this patent protects
The invention provides a liquid formulation comprising epinephrine or a pharmaceutically acceptable salt thereof. The formulation invention includes ascorbic acid and/or a pharmaceutically acceptable salt thereof, an isotonicity agent, and has a pH of about 3.0-5.0. The liquid fo…
USPTO Abstract
The invention provides a liquid formulation comprising epinephrine or a pharmaceutically acceptable salt thereof. The formulation invention includes ascorbic acid and/or a pharmaceutically acceptable salt thereof, an isotonicity agent, and has a pH of about 3.0-5.0. The liquid formulation according to the invention is stable and ready-to-administer.
Drugs covered by this patent
- Levophed (Norepinephrine Bitartrate) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.